Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Inspyr Therapeutics, Inc.v356987_ex99-01.htm

 

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 8, 2013

 

 

 

GENSPERA, INC.

(Exact name of registrant as specified in Charter)

 

 

Delaware   0001421204   20-0438951
(State or other jurisdiction of
incorporation or organization)
  (Commission File No.)   (IRS Employee Identification No.)

 

2511 N Loop 1604 W, Suite 204

San Antonio, TX 78258

(Address of Principal Executive Offices)

 

210-479-8112

(Issuer Telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 
 

 

Item 7.01Regulation FD Disclosure.

 

On October 8, 2013, a representative of GenSpera, Inc. (the “Company”) presented at the 12th Annual Bio Investor Forum at the Palace Hotel in San Francisco, California. Filed herewith as Exhibit 99.01 are the slides that were presented at the luncheon.

 

The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in the exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements of Regulation FD.

  

Item 9.01Financial Statements and Exhibits.

 

Exhibit
No.
  Description
99.01   Slides presented at the 12th Annual Bio Investor Forum

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 8, 2013

  

  GenSpera, Inc.  
     
  By: /s/ Craig Dionne  
    Craig Dionne  
    Chief Executive Officer  

 

 
 

 

INDEX OF EXHIBITS

 

Exhibit
No.
  Description
99.01   Slides presented at the 12th Annual Bio Investor Forum